A prospective study on early detection of chemotherapy-induced cardiotoxicity using myocardial strain and biomarkers in patients with breast cancer
Not Applicable
Active, not recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0005117
- Lead Sponsor
- ational Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- Female
- Target Recruitment
- 83
Inclusion Criteria
female
-Over 19 years old
-Histologically HER-2 positive breast cancer
-Patients who are going to be administered trastuzumab after adjuvant chemotherapy with doxorubicin before surgery or adjuvant chemotherapy with doxorubicin after surgery
-Patients who have written an informed consent
Exclusion Criteria
-Under 18
-Breast cancer patients expected to be treated with chemotherapy that does not contain doxorubicin or trastuzumab
-Patients scheduled to use dexrazoxane
-Patients diagnosed with ischemic heart disease or valve disease
-Patients with atrial fibrillation or atrial fibrillation
-Patients taking angiotensin converting enzyme inhibitors or angiotensin II receptor blockers or beta blockers before chemotherapy
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Early diagnosis of cardiotoxicity as an anti-cancer drug using myocardial deformation of echocardiography
- Secondary Outcome Measures
Name Time Method Confirmation of the incidence of cardiotoxicity by Doxorubicin and Trastuzumab in breast cancer patients;Identification of risk factors involved in cardiotoxicity by Doxorubicin and Trastuzumab in breast cancer patients;Early diagnosis of cardiotoxicity of anticancer drugs using biochemical markers;Investigation of the correlation between the level of TOP2b expression in blood and cardiotoxicity of Doxorubicin